Cargando…
Remdesivir for the treatment of Covid-19: the value of biochemical studies
The nucleotide analogue prodrug remdesivir remains the only FDA-approved antiviral small molecule for the treatment of infection with SARS-CoV-2. Biochemical studies revealed that the active form of the drug targets the viral RNA-dependent RNA polymerase and causes delayed chain-termination. Delayed...
Autor principal: | Götte, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114811/ https://www.ncbi.nlm.nih.gov/pubmed/34052732 http://dx.doi.org/10.1016/j.coviro.2021.04.014 |
Ejemplares similares
-
Remdesivir for COVID-19 in Europe: will it provide value for money?
por: Dal-Ré, Rafael, et al.
Publicado: (2021) -
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
por: Tchesnokov, Egor P., et al.
Publicado: (2019) -
The place for remdesivir in COVID-19 treatment
por: Young, Barnaby, et al.
Publicado: (2021) -
Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020) -
Remdesivir for COVID-19
Publicado: (2020)